Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05511519 · ClinicalTrials.gov registry record · Phase 2
Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis
A Phase 2 study, sponsored by Aclaris Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT05511519 is a Phase 2 study that was terminated before completion, run by Aclaris Therapeutics. The registered enrollment target is 47 participants.
The verdict
NCT05511519, a Phase 2 study, was terminated before completion, sponsored by Aclaris Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
This is a Phase 2a study to investigate the efficacy, safety, tolerability, PK, and PD of ATI-450 versus placebo in patients with moderate to severe psoriatic arthritis.
Interventions
- DRUG Placebo Oral Tablet
- DRUG ATI-450
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2022-07-12 |
| Est. Completion | 2024-01-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05511519
The ClinicalTrials.gov registry entry for NCT05511519 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT05511519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05511519 about?
NCT05511519 is a clinical study titled "Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis". This is a Phase 2a study to investigate the efficacy, safety, tolerability, PK, and PD of ATI-450 versus placebo in patients with moderate to severe psoriatic arthritis.
What is the current status of trial NCT05511519?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2022-07-12. Estimated completion is 2024-01-03.
What interventions are being tested in trial NCT05511519?
The interventions under investigation include: Placebo Oral Tablet (DRUG), ATI-450 (DRUG).
Who is sponsoring clinical trial NCT05511519?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.